Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00848640
Other study ID # 12594
Secondary ID
Status Completed
Phase Phase 2
First received February 19, 2009
Last updated May 25, 2010
Start date October 2008
Est. completion date March 2010

Study information

Verified date September 2009
Source Egyptian Foundation For Cancer Research
Contact n/a
Is FDA regulated No
Health authority Egypt: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date March 2010
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. The patient must provide written informed consent prior to receiving Sorafenib.

2. The male or female patient must be at least 18 years of age.

3. The patient must have pathologically proven advanced Renal Cell Carcinoma.

4. Only patients with measurable disease (According to RECIST) at baseline should be included in protocol where Disease Control Rate (DCR) is the primary endpoint.

5. The patient requires Sorafenib as First line therapy as the patient is unsuitable for another approved first line therapy for advanced RCC.

6. The patient must be, in the Investigator's opinion, reasonably likely to benefit from treatment with Sorafenib as a single agent.

7. The patient must have an Eastern Cooperative Oncology Group performance status of 0 - 2.

8. The patient will not require other systemic anti-cancer chemotherapy, immunotherapy or hormonal therapy, except for bisphosphonates while taking Sorafenib.

9. Both male and female patients must use adequate barrier birth control methods during their participation in the protocol. The birth control methods must be used for 4 weeks for female patients and for 3 months for male patients after discontinuation of treatment with Sorafenib.

10. For patients, who have had major surgery, the wound must be completely healed prior to receiving Sorafenib treatment (4 weeks).

11. The patient must have within normal Renal & Hepatic function.

12. The patient must have within normal CBC.

Exclusion Criteria:

1. Patients who are currently enrolled in or have previously participated in any other Sorafenib trial.

2. Suitable or received any other systemic therapy for treatment RCC (IL-2, INF)

3. Patients who have a life expectancy of less than 2 months.

4. Patients with metastatic brain or meningeal tumours.

5. Patients are excluded who require any of the following:

- Investigational drug therapy during the treatment with Sorafenib or within 30 days prior to their first dose of Sorafenib.

- Concomitant Rifampicin.

6. Non-measurable disease according to RECIST.

7. Concomitant St. John's Wort (Hypericum perforatum).

8. Warfarin (or similar medication) is allowed.

9. Women who are pregnant or breast-feeding. Women of childbearing potential must have a negative pregnancy test performed within seven days of the start of study drug (please note that no laboratory data are collected in this study).

10. Patients with congestive heart failure greater than NYHA functional class II (symptomatic during ordinary activity)

11. Patients with cardiac arrhythmias greater than Grade 1 NCI CTCAE, Version 3.0 (conduction abnormality and supraventricular arrhythmia present but patient is asymptomatic; intervention not indicated, palpitations present and QTc > 0.45 - 0.47 second).

12. Patients with active coronary artery disease or ischemia.

13. Patients with Child-Pugh class C hepatic impairment.

14. Patients with severe renal impairment (calculated creatinine clearance of < 30 ml/min) or who require dialysis.

15. Patients with active uncontrolled hypertension.

16. Patients with recent or active bleeding diathesis.

17. Patients with any medical condition which could jeopardize their safety while taking an investigational drug.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Sorafenib
400 mg twice daily

Locations

Country Name City State
Egypt Egyptian Foundation For Cancer Research Cairo

Sponsors (1)

Lead Sponsor Collaborator
Egyptian Foundation For Cancer Research

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluate the efficacy by evaluating the disease control rate (DCR) and safety of Sorafenib for first line patients unsuitable for another approved first line therapy with advanced RCC in the Middle East region. Disease Control Rate (DCR) defined as either CR, PR or SD for at least 8 weeks Yes
Secondary Quality of life of patient with RCC and Progression Free Survival One year Yes
See also
  Status Clinical Trial Phase
Completed NCT00930033 - Clinical Trial to Assess the Importance of Nephrectomy Phase 3
Recruiting NCT05863351 - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Phase 3
Not yet recruiting NCT06284564 - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Phase 2
Completed NCT00414765 - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Phase 4
Active, not recruiting NCT03149822 - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03647878 - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed NCT01517243 - Phase II Study of Alternating Sunitinib and Temsirolimus Phase 2
Withdrawn NCT03927248 - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT02122003 - Second Line Sorafenib After Pazopanib in Patients With RCC Phase 2
Completed NCT01182142 - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients Phase 2
Completed NCT00630409 - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Completed NCT04076787 - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting NCT04467021 - Cancer and Blood Pressure Management, CARISMA Study N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT02282579 - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Terminated NCT02071641 - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT01731158 - Sequential Therapy in Metastatic Renal Cell Carinoma Phase 2
Terminated NCT01342627 - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma Phase 2
Active, not recruiting NCT01274273 - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer Phase 2